Corium International,Inc. (NASDAQ:CORI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.Submission of Matters to a Vote of Security Holders.
On March 9, 2017, Corium International, Inc. (the Company) held
its annual meeting of stockholders (the Annual Meeting). The
stockholders of the Company voted in person or by proxy at the
Annual Meeting on the following proposals, each of which is
described in more detail in the Companys definitive proxy
statement, filed with the Securities and Exchange Commission on
January 13, 2017:
|
1. |
To elect three Class III directorsto serve as members of |
|
2. |
To ratify the appointment of Deloitte ToucheLLP as the |
The voting results for each of these proposals are detailed
below.
1.Election of Directors
Each of the three nominees for director was elected to serve
until the third annual meeting of stockholders following the
Annual Meeting and until his or her successor has been elected
and qualified or until his or her earlier resignation or removal.
The voting results were as follows:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Peter D. Staple |
18,991,463 |
353,584 |
1,707,849 |
|
Ivan Gergel, M.D. |
18,992,304 |
352,743 |
1,707,849 |
|
Robert W. Thomas |
18,644,813 |
700,234 |
1,707,849 |
2.Ratification of Appointment of Independent Registered Public
Accounting Firm
The stockholders ratified the appointment of Deloitte Touche LLP
as the Companys independent registered public accounting firm for
the fiscal year ending September 30, 2017.The voting results were
as follows:
|
For |
Against |
Abstentions |
|
21,049,643 |
50 |
3,203 |
About Corium International, Inc. (NASDAQ:CORI)
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch. Corium International, Inc. (NASDAQ:CORI) Recent Trading Information
Corium International, Inc. (NASDAQ:CORI) closed its last trading session up +0.07 at 3.69 with 115,508 shares trading hands.
